The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Oklahoma
ClinicalTrials.gov Identifier:
NCT00644657
First received: March 24, 2008
Last updated: September 7, 2011
Last verified: September 2011
  Purpose

This study will explore the effect of clopidogrel on coated-platelets in patients who are given a loading dose before diagnostic catheterization or percutaneous coronary intervention. We hypothesis that clopidogrel will reduce the percentage of platelets that are coated and therefore more hypercoagulable.


Condition Intervention
Coronary Artery Disease
Chest Pain
Drug: Clopidogrel

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

Resource links provided by NLM:


Further study details as provided by University of Oklahoma:

Primary Outcome Measures:
  • The Percentage of Coated Platelets After the Administration of Clopidogrel in Patients Undergoing Cardiac Catheterization and/or Angioplasty [ Time Frame: 24 hours after the administration of clopidotrel ] [ Designated as safety issue: No ]
    The percentage of platelets that are collagen coated after the administration of clopidogrel.


Secondary Outcome Measures:
  • The Percentage of Coated Platelets After Coronary Angiography and/or PCI [ Time Frame: 6 hrs after procedure ] [ Designated as safety issue: No ]
    The percentage of coated platelets 24 hours after coronary angiography and/or PCI


Enrollment: 27
Study Start Date: March 2007
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Clopidogrel
    All subjects will receive a 300 mg loading dose
    Other Name: Plavix
Detailed Description:

Platelet activity will be determined by light transmission aggregometry at baseline, after a 300 mg dose of clopidogrel and after the catheterization and/or angioplasty procedure. The change in the percentage of platelets that are coated platelets will be determined.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients given clopidogrel loading dose before scheduled catheterization or percutaneous intervention

Exclusion Criteria:

  • Acute coronary syndrome
  • Unable to tolerate clopidogrel
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00644657

Locations
United States, Oklahoma
VA Medical Center, 1F187
Oklahoma City, Oklahoma, United States, 73104-5076
Sponsors and Collaborators
University of Oklahoma
Investigators
Principal Investigator: Eliot Schechter, MD University of Oklahoma
  More Information

No publications provided

Responsible Party: University of Oklahoma
ClinicalTrials.gov Identifier: NCT00644657     History of Changes
Other Study ID Numbers: 13291
Study First Received: March 24, 2008
Results First Received: January 6, 2011
Last Updated: September 7, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of Oklahoma:
Platelets, platelet aggregation inhibitors

Additional relevant MeSH terms:
Chest Pain
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Pain
Signs and Symptoms
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Clopidogrel
Platelet Aggregation Inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 13, 2014